Robert H. Fairclough
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Robert H. Fairclough has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Eswari Gudipati
Biochemistry, Siemens Healthcare Diagnostics, 5210 Pacific Concourse Drive, Los Angeles, CA 90045, United States
4 shared publicationsDavid P. Richman
University of California, Davis School of Medicine, Department of Neurology, One Shields Avenue, 1515 Newton Court, Room 510C, Davis, CA 95616, United States; Neurosciences Graduate Group of UC Davis, United States
3 shared publicationsAnthony R. Chuang
‡Drexel University School of Medicine, Philadelphia, Pennsylvania
2 shared publicationsMark A. Agius
University of California, Davis School of Medicine, Department of Neurology, One Shields Avenue, 1515 Newton Court, Room 510C, Davis, CA 95616, United States; VANCHCS, 10535 Hospital Way, Mather, CA 95655, United States
2 shared publicationsMike Y. Lin
Department of Neurology, University of California, Davis, Davis, California 95616, USA
2 shared publicationsThomas E. Lee
VivoSecurity Inc
2 shared publications
Latest Publications
- Open Access
- 30 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (1) , 229
Development of Peptide Mimics of the Human Acetylcholine Receptor Main Immunogenic Region for Treating Myasthenia Gravis
We have designed and produced 39 amino acid peptide mimics of the Torpedo and human acetylcholine receptors’ (AChRs) main immunogenic regions (MIRs). These conformationally sensitive regions consist of three non-contiguous segments of the AChR α-subunits and are the target of 50–70% of the anti-AChR autoantibodies (Abs) in human myasthenic serum and in the serum of rats with a model of that disease, experimental autoimmune myasthenia gravis (EAMG), induced by immunizing the rats with the Torpedo electric organ AChR. These MIR segments covalently joined together bind a significant fraction of the monoclonal antibodies (mAbs) raised in rats against electric organ AChR. Many of these mAbs cross react with the rat neuromuscular AChR MIR and induce myasthenic symptoms when injected into naïve rats. The human MIR mimic peptide (H39MIR) is evolutionarily related to that of the Torpedo electric organ MIR mimic peptide (T39MIR) with eight amino acid differences between the two MIR mimics. The mAbs raised to the electric organ AChR MIR cross react with the human and scores of other species’ neuromuscular AChRs. However, the mAbs do not cross react with the H39MIR mimic attached to the N-terminus of an intein–chitin-binding domain (H39MIR-IChBD) even though they do bind to the T39MIR-IChBD construct. To account for this difference in binding anti-MIR mAbs, each of the eight human amino acids was substituted individually into the T39MIR-IChBD, and four of them were found to weaken mAb recognition. Substituting the corresponding four Torpedo amino acids individually and in combination into the homologous positions in H39MIR-IChBD makes chimeric human MIR mimic peptides (T/H39MIR), some of which bind anti-MIR mAbs and anti-MIR Abs from rat EAMG and human MG sera. The best mAb binding chimeric peptide constructs may potentially serve as the basis of a diagnostic anti-MIR Ab titer assay that is both prognostic and predictive of disease severity. Furthermore, the best peptides may also serve as the targeting element of a non-steroidal antigen-specific treatment of MG to remove anti-AChR MIR Abs, either as fused to the N-terminals of the human immunoglobin Fc fragment or as the targeting component of a T cell chimeric autoantibody receptor (CAAR) directed to anti-MIR memory B cells for elimination.
- 30 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (1) , 229
Open AccessDevelopment of Peptide Mimics of the Human Acetylcholine Receptor Main Immunogenic Region for Treating Myasthenia Gravis
We have designed and produced 39 amino acid peptide mimics of the Torpedo and human acetylcholine receptors’ (AChRs) main immunogenic regions (MIRs). These conformationally sensitive regions consist of three non-contiguous segments of the AChR α-subunits and are the target of 50–70% of the anti-AChR autoantibodies (Abs) in human myasthenic serum and in the serum of rats with a model of that disease, experimental autoimmune myasthenia gravis (EAMG), induced by immunizing the rats with the Torpedo electric organ AChR. These MIR segments covalently joined together bind a significant fraction of the monoclonal antibodies (mAbs) raised in rats against electric organ AChR. Many of these mAbs cross react with the rat neuromuscular AChR MIR and induce myasthenic symptoms when injected into naïve rats. The human MIR mimic peptide (H39MIR) is evolutionarily related to that of the Torpedo electric organ MIR mimic peptide (T39MIR) with eight amino acid differences between the two MIR mimics. The mAbs raised to the electric organ AChR MIR cross react with the human and scores of other species’ neuromuscular AChRs. However, the mAbs do not cross react with the H39MIR mimic attached to the N-terminus of an intein–chitin-binding domain (H39MIR-IChBD) even though they do bind to the T39MIR-IChBD construct. To account for this difference in binding anti-MIR mAbs, each of the eight human amino acids was substituted individually into the T39MIR-IChBD, and four of them were found to weaken mAb recognition. Substituting the corresponding four Torpedo amino acids individually and in combination into the homologous positions in H39MIR-IChBD makes chimeric human MIR mimic peptides (T/H39MIR), some of which bind anti-MIR mAbs and anti-MIR Abs from rat EAMG and human MG sera. The best mAb binding chimeric peptide constructs may potentially serve as the basis of a diagnostic anti-MIR Ab titer assay that is both prognostic and predictive of disease severity. Furthermore, the best peptides may also serve as the targeting element of a non-steroidal antigen-specific treatment of MG to remove anti-AChR MIR Abs, either as fused to the N-terminals of the human immunoglobin Fc fragment or as the targeting component of a T cell chimeric autoantibody receptor (CAAR) directed to anti-MIR memory B cells for elimination.
- Open Access
- 16 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (14) , 7796
Insights into CLC-0’s Slow-Gating from Intracellular Proton Inhibition
The opening of the Torpedo CLC-0 chloride (Cl−) channel is known to be regulated by two gating mechanisms: fast gating and slow (common) gating. The structural basis underlying the fast-gating mechanism is better understood than that of the slow-gating mechanism, which is still largely a mystery. Our previous study on the intracellular proton (H+i)-induced inhibition of the CLC-0 anionic current led to the conclusion that the inhibition results from the slow-gate closure (also called inactivation). The conclusion was made based on substantial evidence such as a large temperature dependence of the H+i inhibition similar to that of the channel inactivation, a resistance to the H+i inhibition in the inactivation-suppressed C212S mutant, and a similar voltage dependence between the current recovery from the H+i inhibition and the recovery from the channel inactivation. In this work, we further examine the mechanism of the H+i inhibition of wild-type CLC-0 and several mutants. We observe that an anion efflux through the pore of CLC-0 accelerates the recovery from the H+i-induced inhibition, a process corresponding to the slow-gate opening. Furthermore, various inactivation-suppressed mutants exhibit different current recovery kinetics, suggesting the existence of multiple inactivated states (namely, slow-gate closed states). We speculate that protonation of the pore of CLC-0 increases the binding affinity of permeant anions in the pore, thereby generating a pore blockage of ion flow as the first step of inactivation. Subsequent complex protein conformational changes further transition the CLC-0 channel to deeper inactivated states.
- 16 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (14) , 7796
Open AccessInsights into CLC-0’s Slow-Gating from Intracellular Proton Inhibition
The opening of the Torpedo CLC-0 chloride (Cl−) channel is known to be regulated by two gating mechanisms: fast gating and slow (common) gating. The structural basis underlying the fast-gating mechanism is better understood than that of the slow-gating mechanism, which is still largely a mystery. Our previous study on the intracellular proton (H+i)-induced inhibition of the CLC-0 anionic current led to the conclusion that the inhibition results from the slow-gate closure (also called inactivation). The conclusion was made based on substantial evidence such as a large temperature dependence of the H+i inhibition similar to that of the channel inactivation, a resistance to the H+i inhibition in the inactivation-suppressed C212S mutant, and a similar voltage dependence between the current recovery from the H+i inhibition and the recovery from the channel inactivation. In this work, we further examine the mechanism of the H+i inhibition of wild-type CLC-0 and several mutants. We observe that an anion efflux through the pore of CLC-0 accelerates the recovery from the H+i-induced inhibition, a process corresponding to the slow-gate opening. Furthermore, various inactivation-suppressed mutants exhibit different current recovery kinetics, suggesting the existence of multiple inactivated states (namely, slow-gate closed states). We speculate that protonation of the pore of CLC-0 increases the binding affinity of permeant anions in the pore, thereby generating a pore blockage of ion flow as the first step of inactivation. Subsequent complex protein conformational changes further transition the CLC-0 channel to deeper inactivated states.
- Open Access
Proton-Dependent Inhibition, Inverted Voltage Activation, and Slow Gating of CLC-0 Chloride Channel
CLC-0, a prototype Cl − channel in the CLC family, employs two gating mechanisms that control its ion-permeation pore: fast gating and slow gating. The negatively-charged sidechain of a pore glutamate residue, E166, is known to be the fast gate, and the swinging of this sidechain opens or closes the pore of CLC-0 on the millisecond time scale. The other gating mechanism, slow gating, operates with much slower kinetics in the range of seconds to tens or even hundreds of seconds, and it is thought to involve still-unknown conformational rearrangements. Here, we find that low intracellular pH (pH i ) facilitates the closure of the CLC-0’s slow gate, thus generating current inhibition. The rate of low pH i -induced current inhibition increases with intracellular H + concentration ([H + ] i )—the time constants of current inhibition by low pH i = 4.5, 5.5 and 6 are roughly 0.1, 1 and 10 sec, respectively, at room temperature. In comparison, the time constant of the slow gate closure at pH i = 7.4 at room temperature is hundreds of seconds. The inhibition by low pH i is significantly less prominent in mutants favoring the slow-gate open state (such as C212S and Y512A), further supporting the fact that intracellular H + enhances the slow-gate closure in CLC-0. A fast inhibition by low pH i causes an apparent inverted voltage-dependent activation in the wild-type CLC-0, a behavior similar to those in some channel mutants such as V490W in which only membrane hyperpolarization can open the channel. Interestingly, when V490W mutation is constructed in the background of C212S or Y512A mutation, the inverted voltage-dependent activation disappears. We propose that the slow kinetics of CLC-0’s slow-gate closure may be due to low [H + ] i rather than due to the proposed large conformational change of the channel protein. Our results also suggest that the inverted voltage-dependent opening observed in some mutant channels may result from fast closure of the slow gate by the mutations.
Open AccessProton-Dependent Inhibition, Inverted Voltage Activation, and Slow Gating of CLC-0 Chloride Channel
CLC-0, a prototype Cl − channel in the CLC family, employs two gating mechanisms that control its ion-permeation pore: fast gating and slow gating. The negatively-charged sidechain of a pore glutamate residue, E166, is known to be the fast gate, and the swinging of this sidechain opens or closes the pore of CLC-0 on the millisecond time scale. The other gating mechanism, slow gating, operates with much slower kinetics in the range of seconds to tens or even hundreds of seconds, and it is thought to involve still-unknown conformational rearrangements. Here, we find that low intracellular pH (pH i ) facilitates the closure of the CLC-0’s slow gate, thus generating current inhibition. The rate of low pH i -induced current inhibition increases with intracellular H + concentration ([H + ] i )—the time constants of current inhibition by low pH i = 4.5, 5.5 and 6 are roughly 0.1, 1 and 10 sec, respectively, at room temperature. In comparison, the time constant of the slow gate closure at pH i = 7.4 at room temperature is hundreds of seconds. The inhibition by low pH i is significantly less prominent in mutants favoring the slow-gate open state (such as C212S and Y512A), further supporting the fact that intracellular H + enhances the slow-gate closure in CLC-0. A fast inhibition by low pH i causes an apparent inverted voltage-dependent activation in the wild-type CLC-0, a behavior similar to those in some channel mutants such as V490W in which only membrane hyperpolarization can open the channel. Interestingly, when V490W mutation is constructed in the background of C212S or Y512A mutation, the inverted voltage-dependent activation disappears. We propose that the slow kinetics of CLC-0’s slow-gate closure may be due to low [H + ] i rather than due to the proposed large conformational change of the channel protein. Our results also suggest that the inverted voltage-dependent opening observed in some mutant channels may result from fast closure of the slow gate by the mutations.
- 9 May 2017
- Published by Springer Nature
- p. 65-80
Structural Insights from Membrane Small-Angle X-ray Diffraction with Anomalous X-ray Scattering
- 9 May 2017
- Published by Springer Nature
- p. 65-80
Structural Insights from Membrane Small-Angle X-ray Diffraction with Anomalous X-ray Scattering
- 1 May 2014
- Published by Elsevier in Molecular Immunology
- Vol. 59 (1) , 79-90
Design, synthesis, and characterization of a 39 amino acid peptide mimic of the main immunogenic region of the Torpedo acetylcholine receptor
- 1 May 2014
- Published by Elsevier in Molecular Immunology
- Vol. 59 (1) , 79-90
Design, synthesis, and characterization of a 39 amino acid peptide mimic of the main immunogenic region of the Torpedo acetylcholine receptor
- 1 March 2014
- Published by Elsevier in Molecular Immunology
- Vol. 58 (1) , 116-131
Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor
- 1 March 2014
- Published by Elsevier in Molecular Immunology
- Vol. 58 (1) , 116-131
Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor
- 1 April 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (7) , 2637-2647
Redistribution of Terbium Ions Across Acetylcholine Receptor-Enriched Membranes Induced by Agonist Desensitization
- 1 April 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (7) , 2637-2647
Redistribution of Terbium Ions Across Acetylcholine Receptor-Enriched Membranes Induced by Agonist Desensitization
- 15 August 2006
- Published by Elsevier in Biophysical Journal
- Vol. 91 (4) , 1143-1144
Recalled to Life: Resurrection of Diffusion-Enhanced Fluorescence Energy Transfer
- 15 August 2006
- Published by Elsevier in Biophysical Journal
- Vol. 91 (4) , 1143-1144
Recalled to Life: Resurrection of Diffusion-Enhanced Fluorescence Energy Transfer
- 1 September 2003
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 998 (1) , 101-113
Agonist-induced transitions of the acetylcholine receptor.
- 1 September 2003
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 998 (1) , 101-113
Agonist-induced transitions of the acetylcholine receptor.
- 1 September 1998
- Published by Elsevier in Journal of Molecular Biology
- Vol. 282 (2) , 317-330
Differential surface accessibility of α(187–199) in the Torpedo acetylcholine receptor α subunits 1 1Edited by B. Holland
- 1 September 1998
- Published by Elsevier in Journal of Molecular Biology
- Vol. 282 (2) , 317-330
Differential surface accessibility of α(187–199) in the Torpedo acetylcholine receptor α subunits 1 1Edited by B. Holland